Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

EKF Diagnostics’ Quo-Lab HbA1c Analyzer Secures IFCC Certification

Published: Friday, January 10, 2014
Last Updated: Friday, January 10, 2014
Bookmark and Share
Point-of-care analyzer meets all standards set by independent certifying bodies.

EKF Diagnostics has announced that its Quo-Lab HbA1c point-of-care analyzer has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification.

The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.

To participate in the program manufacturers are required to register and report the results of twenty four samples (two per month) from across the measurement range. The samples are supplied by an IFCC Reference Laboratory.

“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, Diabetes Product Manager EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.”

Glycated hemoglobin (HbA1c) testing is globally recognized as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management.

The Quo-Lab analyzer offers laboratory accurate results from just 4 µL of blood with a user friendly interface, simplifying the process even further.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
Combined with the recent acquisition of Seperation Technology the purchases strengthen EKF’s product and services offering.
Tuesday, April 22, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos